DNMT3A and acute myeloid leukemia: Survival analysis verified that the DNMT3A R882 mutation AML patients showed markedly shorter median OS and DFS compared with R882 wildtype patients (R882 mutation: 212 days vs R882 wildtype: 560 days, P<0.0001 for OS; R882 mutation: 228 days vs R882 wildtype: 469 days, P=0.004 for DFS, Figure 2G, 2H).